New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
March 28, 2022 - UCB announced the FDA approval of Fintepla (fenfluramine), for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
Download PDF
Return to publications
